EGFR and cancer: Because the EGFR non-covalent inhibitor was prone to generate drug resistance during the treatment of cancer patients, the second-generation EGFR inhibitor afatinib was active at nanomolar levels in lung cancer cells through the covalent attachment to Cys797 of the mutant EGFR [37].